Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Gestational diabetes is associated with SARS-CoV-2 infection during pregnancy: A case-control study

Anda-Petronela Radan*, Mihaela-Madalina Fluri, Konstantinos Nirgianakis, Beatrice Mosimann, Bettina Schlatter, Luigi Raio, Daniel Surbek

Department of Obstetrics and Feto-Maternal Medicine, University Hospital of Bern, University of Bern, Friedbuhlstrasse 19, Bern CH-3010, Switzerland

ARTICLE INFO

Article History:
Received 31 January 2022
Revised 28 March 2022
Accepted 4 April 2022
Available online 21 April 2022

Keywords:
SARS-CoV-2
Gestational diabetes
COVID-19

Abstract

Aim: Individuals with SARS-CoV-2 infection and (pre-existing) diabetes, including pregnant women, present with more severe morbidity, as compared to non-diabetic subjects. To date, evidence is limited concerning the role of gestational diabetes (GDM) in severity of SARS-CoV-2 infection during pregnancy, or vice versa. The aim of our study was to investigate the prevalence of GDM in a SARS-CoV-2 infected pregnant population and evaluate risk factors for and from severe infection in these patients.

Methods: A case-control study with prospective data collection for the case group and 1:2 matching with historical controls based on parity, BMI and ethnicity was conducted (n = 224). GDM screening was performed at 26 weeks’ gestation. Multivariate binary logistic regression analysis was performed to assess risk factors for GDM and inpatient COVID-19 management.

Results: 34.6% of the patients in the case group suffered from GDM, vs. 16.1% in the control group (p = 0.002). 35.7% patients were diagnosed with GDM after, vs. 33.3% before SARS-CoV-2 infection (OR (95%CI) 1.11 (0.40 – 3.08), p = 0.84), with no correlation between time point of infection and GDM diagnosis. SARS-CoV-2 (OR (95%CI) 2.79 (1.42, 5.47), p = 0.003) and BMI (OR (95%CI) 1.12 (1.05, 1.19), p = 0.001) were significant independent risk factors for GDM.

Conclusion: Data suggests that GDM increases the risk of infection in SARS-CoV-2 infected pregnant women. Meanwhile, SARS-CoV-2 during pregnancy might increase the risk of developing GDM. Vaccination and caution in using protective measures should be recommended to pregnant women, particularly when suffering from GDM.

© 2022 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Diabetes mellitus (DM) is one of the most frequent comorbidities in individuals with SARS-CoV-2 infection [1,2]. Evidence shows that individuals suffering from diabetes present higher morbidity and mortality as compared to non-diabetic subjects [1].

Analogue to the general population, pregnant women suffering from preexisting diabetes seem to present with a higher severity degree of SARS-CoV-2 infection [3,4]. An international case control analysis comparing data stratified by the severity of maternal disease identified pulmonary comorbidities, hypertensive disease and DM as risk factors associated with a severe form of SARS-CoV-2 infection in pregnancy [5]. Furthermore, it has been previously suggested that hyperglycemia generally increases viral replication and decreases anti-viral response, making a causal relationship between diabetes and SARS-CoV-2 biologically plausible [1,2]. However, there is limited data so far whether these elaborations also apply to gestational diabetes (GDM).

GDM is a major public health issue, with an abrupt increase in prevalence in the last decade, and international committees report a so-called ‘metabolic pandemic’ [6]. According to The Hyperglycemia and Adverse Pregnancy Outcome Study, the level of glycaemia during pregnancy is directly linked to the presence of adverse obstetrical outcomes [7,8].

Prevalence of GDM lies worldwide between 9.3% and 25.5% [8]. A British study described a 33.8% increase in GDM since the onset of the pandemic, attributing this mainly to reduced exercise levels and psychical stress [9].

SARS-CoV mediated pancreatic islet cell damage is not a newly described phenomenon, as earlier experiences with MERS and SARS teach us [10]. DM is a multifactorial disease, and its development is linked to genetic and environmental influences. Indeed, a causal relationship between viral infections and acute glycemic decompensation with onset of Type I diabetes has been previously described [11].

* Corresponding author.
E-mail address: anda-petronela.radan@insel.ch (A.-P. Radan).
In this context, increasing evidence shows that SARS-CoV-2 can trigger severe diabetic ketoacidosis in persons with new-onset Type 1 diabetes, most probably due to high angiotensin converting enzyme 2 (ACE2) expression in the endocrine part of the pancreas. The mechanism seems to involve cell apoptosis with decreased pancreatic insulin secretion [11].

The aim of our study was to investigate the prevalence of GDM in a SARS-CoV-2 infected pregnant population and evaluate risk factors for and from severe infection in these patients.

**Methods**

We included 224 pregnant women in our case-control study. The case group consisted of 75 women with SARS-CoV-2 infection during pregnancy, irrespective of the severity of the symptoms. We included all SARS-CoV-2 positive women who were managed at our tertiary hospital between May 2020 and July 2021. Data from these individuals were collected prospectively within the international COVI-Preg register. Cases were matched 1:2 with a historical cohort of women who delivered before the SARS-CoV-2 pandemic between 01.01.2016 and 31.10.2019, based on parity, body mass index (BMI) and ethnicity. In one woman, only one matching control was found, so that the control group consisted of 149 individuals. Screening for GDM by a 75 mg oral glucose tolerance test (OGTT) was performed at 26 weeks’ gestation in all 224 women. Normal blood sugar values were defined as follows: fasting <5.1 mmol/l, one hour after glucose ingestion <10 mmol/l, two hours after glucose ingestion <8.5 mmol/l. All women where OGTT was not available were previously excluded.

First trimester was defined as conception to 13 + 6 weeks, second trimester from 14 + 0 to 26 + 6 weeks and third trimester as more than 27 + 0 weeks of gestation.

Diagnosis of COVID-19 infection in the case group was made by identification of SARS-CoV-2-PCR in a nasopharyngeal swab.

Written informed consent was obtained, institutional review board approval was provided by the Ethical Committee of Berne (2020 –00,382). The study was performed in accordance with the principles of the Declaration of Helsinki. No external funding was received.

**Statistical analysis**

Mean values and SD were calculated for continuous variables and percentages for the qualitative variables. A student t-test and Fisher’s exact test was used to compare continuous parametric variables and binary variables between the two groups, respectively. Possible risk factors for gestational diabetes and inpatient COVID-19 management were determined with multivariate binary logistic regression analysis. A logistic regression analysis was also performed to identify if the time of COVID-19 infection during pregnancy was associated with GDM. Missing data were excluded from the analysis. Significance was set at p < 0.05. Statistical analysis was carried out with SPSS 25.0 software (SPSS, USA).

**Results**

Baseline characteristics of the study population and delivery outcomes are depicted in Table 1. Altogether, 26/75 (34.66%) of the patients in the case group suffered from gestational diabetes vs. 24/149 (16.1%) in the control group (p = 0.002). The rate of preterm delivery was 17.3% in the case group vs. 7.6% in the control group (p = 0.04).

Multivariate logistic regression analysis revealed that SARS-CoV-2 (OR (95%CI) 2.79 (1.42, 5.47), p = 0.003) and BMI (OR (95%CI) 1.12 (1.05, 1.19), p = 0.001) were significant independent risk factors for GDM.

In 11/75 (14.66%) patients, SARS-CoV-2 infection occurred in the first trimester of gestation, in 19/75 (25.33%) in the second and in 37/75 (49.33%) in the third trimester. In eight patients, time-point of infection was unknown (10.66%). Of these, three suffered from GDM.

Out of 28 patients infected with COVID-19 ≤ 26 week of pregnancy, 10 (35.7%) had a positive OGTT (GDM diagnosis) afterwards. This is similar to the 13/39 (33.3%) of patients with positive OGTT before infected with COVID (OR (95%CI) 1.10 (0.40, 3.08, Chi-Square = 0.84).

89.33% of the patients (67/75) in the case group suffered from asymptomatic, mild or moderate SARS-CoV-2 infection, according to the National Institutes of Health (NIH) criteria for severity of the disease [12]. 12% (9/75) of the patients had severe or critical illness with inpatient management. Of these, 5.33% (4/75) required intensive care unit (ICU) admission and ventilation. These four patients underwent an emergency delivery because of SARS-CoV-2 infection. No patient deaths were recorded.

Of the nine patients with inpatient management, four (44.44%) suffered from GDM. Of the four patients who required admission at the ICU, two suffered from GDM (50%). Of the 66 patients with outpatient management, 22 suffered from GDM (33.33%). This difference was not significant in chi-square test (p = 0.51). Regression analysis

| Table 1 |
| --- |
| Comparison of baseline characteristics and pregnancy outcomes between the two groups. |
| Characteristics | Cases n = 75 | Controls n = 149 | P value |
| Age | 30.76 ± 4.63 | 30.62 ± 4.48 | ns |
| BMI (kg/m²) | 26.27 ± 5.08 | 25.91 ± 5.03 | ns |
| Parity | 1 (0–7) | 1 (0–5) | ns |
| Ethnicity | | |
| Caucasian | 60 (80) | 120 (80) | ns |
| African | 11 (14.7) | 21 (14.1) | ns |
| South Asia | 2 (2.7) | 4 (2.7) | ns |
| East Asia | 1 (1.3) | 2 (1.3) | ns |
| Mixed | 1 (1.3) | 2 (1.3) | ns |
| Twins | 1 (1.3) | 4 (2.7) | ns |
| GDM | 26/75 (34.7) | 24/149 (16.1) | 0.002 |
| SGA/IUGR | 9/70 (12.9) | 13/139 (9.4) | ns |
| Mode of delivery | | |
| Spontaneous vaginal delivery | 31/66 (47) | 69/140 (49.3) | ns |
| Operative vaginal delivery | 6/66 (9.1) | 15/140 (10.7) | ns |
| Primary cesarean section | 19/66 (28.8) | 29/140 (20.7) | ns |
| Secondary cesarean section | 10/66 (15.2) | 27/140 (19.3) | ns |
| 5Min. Apgar score | 7.25 ± 0.078 | 7.18 ± 0.683 | ns |
| Fetal transfer to the ICU | 7/66 (10.6) | 8/136 (5.9) | ns |

*missing values were excluded from the analysis.*
of factors associated with inpatient COVID-19 management (inpatient vs. outpatients) showed no significance for GDM (OR (95%CI) 1.14 (0.22, 5.80), p = 0.88), time-point of infection (OR (95%CI) 1.08 (0.98, 1.20), p = 0.12) or BMI (OR (95%CI) 1.07 (0.91, 1.25), 0.41).

Discussion

The main finding of our study is a significantly higher incidence of GDM in a SARS-CoV-2 infected pregnant population, as compared to historical controls. All though no statistical correlation was found between the time point of infection in regards to OGTT, previous data concerning DM and COVID-19 during pregnancy would support in a first line that those patients with GDM are more prone to SARS-CoV-2 infection. Meanwhile, multivariate regression analysis revealed that BMI and COVID-19 were independent risk factors for GDM in our cohort, thus supporting the theory of the virus-triggered diabetes onset.

A recently published multicentric study also reported an association between insulin dependent GDM and COVID-19 diagnosis in pregnancy, yet over 80% of the participants were SARS-CoV-2 positive at the time-point of delivery, thus chronologically after diagnosis of GDM [13]. Our report is to our knowledge the first case-control study providing evidence, even if limited, for a possible causal relationship between COVID-19 and onset of GDM.

As stated before, the hyperglycemic level directly correlates with adverse obstetrical outcome [7,8]. Incidence of GDM was higher in the SARS-CoV-2 hospitalized patients (44.44% vs. 33.33% in those with outpatient management), yet this difference was marginally not statistically significant (p = 0.51). Meanwhile, 50% of the women requiring ICU admission in our cohort suffered from GDM, which is alarming. On a deeper analysis, BMI, GDM and time point of infection none correlated with inpatient management of SARS-CoV-2 infection, thus with the degree of severity. Since previous large reports could clearly show a correlation between high BMI and severity of infection, we believe that our results are a consequence of the small number of patients with inpatient management and ICU admission, thus lack of statistical power to demonstrate a possible association [5].

With an European rate of GDM of 16.3% and worldwide of up to 25.5%, these results are of concern and call for consequences in the management of pregnant patients suffering from GDM or at risk for GDM in the context of the pandemic [7,8].

Higher exposition to hospital visits in women suffering from GDM could be confounding factor for SARS-CoV-2 infection in pregnancy. We mention that patient management was adapted in our center during the major SARS-CoV-2 pandemic surges, mostly by conversion to teleconsultations. Diabetes testing protocols remained unaltered. In both our study groups, GDM rate was higher than in the general pregnant population in Switzerland, which could be explained by the higher proportion of high-risk pregnancies as well as by the high number of women with South Asian ethnicity being followed at our institution [8].

The rate of hospital admission in SARS-CoV-2 infection in our population was in line with previous reports [5]. We noted a significantly higher incidence of premature delivery in the case group, whereas in the control group, incidence was similar to that of the general pregnant population in our country [14]. The 17.33% rate of preterm delivery in the SARS-CoV-2 infected women in our cohort is in line with results from a large previous meta-analysis [15].

One major strength of our report is the prospective data assessment in the case group and the case-control approach. Homogeneity of testing is another major strength, since standard OGTT was carried out in each patient in both groups, which distinguishes us from previous publications. The ability to classify the COVID-19 infection in respect to the symptoms is a further strength of our study. The major limitation is the cohort size as well as not having matched for further comorbidities or lower socioeconomic status, which is a known risk factor for both GDM as well as SARS-CoV-2 infection, because of incomplete records.

Conclusion

The significantly higher rate of GDM among women with SARS-CoV-2 infection during pregnancy, as compared to corresponding controls, suggests that GDM increases the risk of infection. Meanwhile, SARS-CoV-2 during pregnancy might increase the risk of developing GDM. Vaccination and caution in using protective measures should be recommended to pregnant women, particularly those with co-morbidities.

CRediT authorship contribution statement

Anda-Petronela Radan: Conceptualization, Data curation, Formal analysis, Writing – original draft, Investigation. Mihaela-Madalina Fluri: Formal analysis, Data curation, Investigation. Konstantinos Nirgianakis: Formal analysis, Data curation, Visualization, Writing – review & editing. Beatrice Mosimann: Data curation, Writing – review & editing. Bettina Schlatter: Data curation. Luigi Raio: Formal analysis, Data curation, Writing – review & editing. Daniel Surbek: Conceptualization, Writing – review & editing.

Funding information

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest

The author(s) report(s) no conflict of interest.

References

[1] Hartmann-Boyce J, Rees K, Perring JC. Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews. Diabetes Care 2021;44(12):2790–811. Epub 2021 Oct 28. Erratum in: Diabetes Care. 2022 Mar 09; PMID: 34711637; PMCID: PMC8669527. doi:10.2337/dc21-0930.
[2] Stravdas AJ, Bogun MM, McMahon DJ. Diabetic ketoacidosis and mortality in COVID-19 infection. Diabetes Metab 2021;47(4):101267. Epub 2022 Dec 36. doi: 10.1161/diabetologia.2021.101267. [3] De Almeida-Pittrof B, Daulib PM, Zajdenverg L, Rodrigues Dantas J, Dias de Souza F, Rodeck M. Severity and mortality of COVID-19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr 2020;12:75.
[4] Radan AP, Baud D, Favre C, Papadia A, Surbek D, Baumann M, Raio L. Low placentental weight and altered metabolic scaling after severe acute respiratory syndrome coronavirus type 2 infection during pregnancy: a prospective multicentric study. Clin Microbiol Infect 2022 Feb 10:S1198-743X(22)00076-3 Epub ahead of print. PMID: 35150886; PMCID: PMC8628389. doi: 10.1016/j.clinmicin.2022.02.003.
[5] Vouga M, Favre C, Martinez-Perez O. Maternal outcomes and risk factors for COVID-19 severity among pregnant women. Sci Rep 2021;11:13898. doi:10.1038/s41598-021-92357-7.
[6] Michael E, Singer Kevin A. The type 2 diabetes ‘modern preventable pandemic’ and replicable lessons from the COVID-19 crisis. Prev Med Rep 2022;25:101616. ISSN 2211-3355. doi:10.1016/j.pmedr.2021.101636.
[7] International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33(3):676–82. doi:10.2337/dc09-1848.
[8] Metzger BE, Lowe LP, Dyer AR, Trimble ER, Coustan DR. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358(19):1991–2002.
[9] Cauldwell M, van-de-Ulde Y, Watt Coote I, Steer PJ. Seasonal and SARS-CoV-2 pandemic changes in the incidence of gestational diabetes. BJOG 2021: doi:10.1111/1471-0528.16775.
[10] Navand AH, Soltani S, Moghadam M, Hossein P, Nasmadzhad S, Zandi M. Diabetes and coronavirus infections (SARS-CoV, MERS-CoV, and SARS-CoV-2). J Acute Dis 2020;9:244–7.
[11] Wu CT, Lidsky PV, Xiao Y. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab. 2021;33(Issue 8). doi:10.1016/j.cmet.2021.05.013.
[12] National Institutes of Health (NIH). Clinical spectrum of SARS-CoV-2 infection. October 2021. Available at: https://www.covid19treatmentguidelines.nih.gov/.
[13] Eskenazi B, Rauch S, Iurlaro E. Diabetes mellitus, maternal adiposity, and insulin-dependent gestational diabetes are associated with COVID-19 in pregnancy: the INTERCOVID Study. Am. J. Obstet. Gynecol. 2022. doi: 10.1016/j.ajog.2021.12.032.

[14] Radan AP, Aleksandra Polowy J, Heverhagen A. Cervico-vaginal placental α-macroglobulin-1 combined with cervical length for the prediction of preterm birth in women with threatened preterm labor. Acta Obstet Gynecol Scand 2020;99(3):357–63 Mar Epub 2019 Oct 28. PMID: 31587255. doi: 10.1111/aogs.13744.

[15] Allotey J, Stallings E, Bonet M, for PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020;370 Sep 1m3320 PMID: 32873575; PMCID: PMC7459193. doi: 10.1136/bmj.m3320.